Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today and ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

The issue with placing it on the floodplain is that it reduces the available area for floodwaters to spread out and slow down,” one neighbor said.

Priority review, which shortens the standard ten-month FDA review timeline to six months, is typically reserved for drugs that provide a significant improvement in safety or efficacy.

The FDA has granted Priority Review to durvalumab for the treatment of resectable, early-stage and locally advanced (Stage II-IVA) gastric and gastroesophageal junction cancers.

The Citi Strata Elite was built to compete with some of the most popular travel credit cards, and its $595 annual fee ...